LOX and neoplasm: Eribulin also showed a much wider in vivo therapeutic window as compared to paclitaxel (five-fold vs. <2.0 in LOX and four-fold vs. 1.7 in MDA-MB-435 models), which can lead to the possibility of increasing the dosage above a fully tumor-suppressive dose, which can subsequently lead to more complete tumor eradication and can explain its superiority over paclitaxel [7,18].